NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
Clinical Trials
7 trialsNCT03766490 2019-01-30
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT03602027 2018-07-26
Phase I Study of the Combination of Anlotinib With Gefitinib
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT03381430 2017-12-22
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Qilu Pharmaceutical Co., Ltd.
Phase NA Unknown
NCT02282267 2017-02-24
Benefit
Peking University Cancer Hospital & Institute
Phase NA Unknown
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT01776684 2013-01-28
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Samsung Medical Center
Phase NA Unknown